The Lab4P Consortium of Probiotics Attenuates Atherosclerosis in LDL Receptor Deficient Mice Fed a High Fat Diet and Causes Plaque Stabilization by Inhibiting Inflammation and Several Pro-atherogenic Processes.

Abstract

SCOPE\nPrevious studies showed that Lab4 probiotic consortium plus Lactobacillus plantarum CUL66 (Lab4P) reduced diet-induced weight gain and plasma cholesterol levels in C57BL/6J mice fed a high fat diet (HFD). The effect of Lab4P on atherosclerosis is not known and was therefore investigated.\n\n\nMETHODS AND RESULTS\nAtherosclerosis-associated parameters were analyzed in LDL receptor deficient mice fed HFD for 12 weeks alone or supplemented with Lab4P. Lab4P increased plasma HDL and triglyceride levels and decreased LDL/VLDL levels. Lab4P also reduced plaque burden and content of lipids and macrophages, indicative of dampened inflammation, and increased smooth muscle cell content, a marker of plaque stabilization. Atherosclerosis arrays showed that Lab4P altered the liver expression of 19 key disease-associated genes. Lab4P also decreased the frequency of macrophages and T-cells in the bone marrow. In vitro assays using conditioned media from probiotic bacteria demonstrated attenuation of several atherosclerosis-associated processes in vitro such as chemokine-driven monocytic migration, proliferation of monocytes and macrophages, foam cell formation and associated changes in expression of key genes, and proliferation and migration of vascular smooth muscle cells.\n\n\nCONCLUSION\nThis study provides new insights into the anti-atherogenic actions of Lab4P together with the underlying mechanisms and supports further assessments in human trials. This article is protected by copyright. All rights reserved.